Sekisui Medical Co., Ltd.

Daiichi Pure Chemicals Co., Ltd.

Kazuo Kotani

Masanao Matsuo

Hirokazu Yago

Yuka Akimoto

Kazunori Saito

Osamu Miyazaki

Yuki Honjo

Hiroyuki Ebinuma

Yasushi Saito

Isamu Fukamachi

Hideaki Bujo

Kohei Takubo

Chiaki Nakaseko

Akiko Suzuki

Kyoko Tanaka

Provided is a method for quantifying soluble LR11 in a biological sample such as serum by an immunological means conveniently and accurately without the need of carrying out any complicated separation manipulation. An immunological quantification method for soluble LR11 in a sample derived from a mammal, including a step of treating the sample with at least one surfactant selected from a group consisting of a polyoxyalkylene alkyl ether, a polyoxyalkylene alkyl phenyl ether, an alkyl glycoside, an alkylthio glycoside, an acyl-N-methylglucamide and a salt of cholic acid.

Method for quantification of soluble LR 11

To provide a method and a diagnostic kit for determining the presence of a malignant tumor or the severity thereof, a method for selecting a therapeutic method therefor or evaluating the effect of the therapeutic method, or a method for estimating the risk of recurrence of the malignant tumor or determining the presence or absence of the recurrence. The method for determining the presence of a malignant tumor or the severity thereof, method for selecting a therapeutic method therefor or evaluating the effect of the therapeutic method, or method for estimating the risk of recurrence of the malignant tumor or the presence or absence of the recurrence is characterized by including 1) a step of measuring the concentration and/or quantity of soluble LR11 in a sample originating from a subject and 2) a step of comparing the value measured above with a measurement value of soluble LR11 obtained from a healthy subject group.

Method for diagnosing malignant tumor

The present invention is directed to a monoclonal antibody against a soluble fibrin, which specifically recognizes a conformation-changed site newly occurred in a C-terminal region of an A&#x3b1;-chain of the soluble fibrin formed through thrombin digestion of fibrinogen. The present invention is also directed to a hybridoma which produces the antibody, an immunological assay method employing the antibody, and a method for evaluating hypercoagulability in a test sample by measuring the soluble fibrin level in the sample with the assay method. Through employment of the monoclonal antibody of the present invention, soluble fibrin on which plasmin has not acted, which reflects exclusively initial hypercoagulability, can be specifically detected.

Anti-human soluble fibrin monoclonal antibody and immunological assay method using the antibody

Growing community of inventors

Ryugasaki, Japan

Masanao Matsuo